Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.46 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3864427 | 0.86 | MGLL (0.44) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL3864424 | 0.86 | MGLL (0.44) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL17924880 | 0.86 | MGLL (0.44) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL31071892 | 0.85 | MGLL (0.35) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL709030 | 0.84 | MGLL (0.46) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL11927409 | 0.84 | MGLL (0.46) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL17924896 | 0.81 | MGLL (0.45) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL8097844 | 0.80 | MGLL (0.48) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL9183909 | 0.80 | MGLL (0.42) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL20706595 | 0.80 | MGLL (0.31) | MGLLFAAHALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739337-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS COMPRISING PANCREATIC ENZYMES | Perseo Pharma AG (CH) | 2026-05-13 | — | — | EP | claimed |
| EP-4739338-A1 | FUNCTIONALIZED DISACCHARIDASE COMPOSITIONS | Perseo Pharma AG (CH) | 2026-05-13 | — | — | EP | claimed |
| EP-4739348-A1 | BIOCATALYTICAL COMPOSITIONS | Perseo Pharma AG (CH) | 2026-05-13 | — | — | EP | claimed |
| EP-4739336-A2 | METHOD FOR IMMOBILIZATION OF PROTEINS | Perseo Pharma AG (CH) | 2026-05-13 | — | — | EP | claimed |
| CN-112533640-B | Targeting of M2-type tumor-associated macrophages using melittin-based apoptosis-inducing peptides | 双亥生命科学株式会社 | 2025-02-28 | — | — | CN | claimed |
| WO-2025008445-A1 | FUNCTIONALIZED DISACCHARIDASE COMPOSITIONS | PERSEO PHARMA AG (CH) | 2025-01-09 | — | — | WO | claimed |
| WO-2025010117-A1 | INFLUENZA B HEADLESS HA UNIVERSAL VACCINES | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-01-09 | — | — | WO | claimed |
| WO-2025008458-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS COMPRISING PANCREATIC ENZYMES | PERSEO PHARMA AG (CH) | 2025-01-09 | — | — | WO | claimed |
| WO-2025008476-A2 | METHOD FOR IMMOBILIZATION OF PROTEINS | PERSEO PHARMA AG (CH) | 2025-01-09 | — | — | WO | claimed |
| WO-2025008442-A1 | BIOCATALYTICAL COMPOSITIONS | PERSEO PHARMA AG (CH) | 2025-01-09 | — | — | WO | claimed |
| WO-2007122259-A1 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS. APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-11-01 | — | — | WO | claimed |
| US-20070254311-A1 | Covalent modification and conjugation of luciferase | CARDIOGENICS INC. (CA) | 2007-11-01 | — | — | US | claimed |
| WO-2006094826-A2 | METHOD FOR COUPLING ENZYMATICALLY ACTIVATED GLYCOCONJUGATES TO A HYDROXYALKYL STARCH | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2006-09-14 | — | — | WO | claimed |
| US-20060165677-A1 | DELETION FORMS OF IgE-DEPENDENT HISTAMINE RELEASING FACTOR HAVING HISTAMINE RELEASING ACTIVITY, HRF-BINDING PEPTIDES AND THE USES THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2006-07-27 | — | — | US | claimed |
| EP-1683866-A2 | Deletion forms of IgE-dependent histamine releasing factor having histamine-releasing activity, HRF-binding peptides and the uses thereof | Ewha University-Industry Collaboration Foundation (KR) | 2006-07-26 | — | — | EP | claimed |
| US-20060100163-A1 | Pharmaceutically active oligosaccharide conjugates | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2006-05-11 | — | — | US | claimed |
| US-20050176642-A1 | Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric GP120 | UNIVERSITY OF MARYLAND, BALTIMORE | 2005-08-11 | — | — | US | claimed |
| EP-1549350-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | Fresenius Kabi Deutschland GmbH (DE) | 2005-07-06 | — | — | EP | claimed |
| WO-2004032971-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | claimed |
| US-20030152932-A1 | Detection method using dissociated rolling circle amplification | QIAGEN GMBH (DE) | 2003-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176642-A1 | Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric GP120 | CD4, CD40LG, NECTIN4 | MGLL 2728/4885FAAH 4698/4885ALDH1A1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.